These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 30790446)

  • 1. Index of microvascular resistance to assess the effect of rosuvastatin on microvascular function in women with chest pain and no obstructive coronary artery disease: A double-blind randomized study.
    Solberg OG; Stavem K; Ragnarsson A; Beitnes JO; Skårdal R; Seljeflot I; Ueland T; Aukrust P; Gullestad L; Aaberge L
    Catheter Cardiovasc Interv; 2019 Nov; 94(5):660-668. PubMed ID: 30790446
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ranolazine improves angina in women with evidence of myocardial ischemia but no obstructive coronary artery disease.
    Mehta PK; Goykhman P; Thomson LE; Shufelt C; Wei J; Yang Y; Gill E; Minissian M; Shaw LJ; Slomka PJ; Slivka M; Berman DS; Bairey Merz CN
    JACC Cardiovasc Imaging; 2011 May; 4(5):514-22. PubMed ID: 21565740
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact of pravastatin pre-treatment on periprocedural microcirculatory damage in patients undergoing percutaneous coronary intervention.
    Fujii K; Kawasaki D; Oka K; Akahori H; Iwasaku T; Fukunaga M; Eguchi A; Sawada H; Masutani M; Lee-Kawabata M; Tsujino T; Ohyanagi M; Masuyama T
    JACC Cardiovasc Interv; 2011 May; 4(5):513-20. PubMed ID: 21596324
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease.
    Yusuf S; Bosch J; Dagenais G; Zhu J; Xavier D; Liu L; Pais P; López-Jaramillo P; Leiter LA; Dans A; Avezum A; Piegas LS; Parkhomenko A; Keltai K; Keltai M; Sliwa K; Peters RJ; Held C; Chazova I; Yusoff K; Lewis BS; Jansky P; Khunti K; Toff WD; Reid CM; Varigos J; Sanchez-Vallejo G; McKelvie R; Pogue J; Jung H; Gao P; Diaz R; Lonn E;
    N Engl J Med; 2016 May; 374(21):2021-31. PubMed ID: 27040132
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of Lipoproteins, Insulin Resistance, and Rosuvastatin With Incident Type 2 Diabetes Mellitus : Secondary Analysis of a Randomized Clinical Trial.
    Dugani SB; Akinkuolie AO; Paynter N; Glynn RJ; Ridker PM; Mora S
    JAMA Cardiol; 2016 May; 1(2):136-45. PubMed ID: 27347563
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Phase III, Multicenter, Randomized, Double-blind, Active Comparator Clinical Trial to Compare the Efficacy and Safety of Combination Therapy With Ezetimibe and Rosuvastatin Versus Rosuvastatin Monotherapy in Patients With Hypercholesterolemia: I-ROSETTE (Ildong Rosuvastatin & Ezetimibe for Hypercholesterolemia) Randomized Controlled Trial.
    Hong SJ; Jeong HS; Ahn JC; Cha DH; Won KH; Kim W; Cho SK; Kim SY; Yoo BS; Sung KC; Rha SW; Shin JH; Han KR; Chung WS; Hyon MS; Lee HC; Bae JH; Rhee MY; Kwan J; Jeon DW; Yoo KD; Kim HS
    Clin Ther; 2018 Feb; 40(2):226-241.e4. PubMed ID: 29402522
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of ACE-inhibition on coronary microvascular function and symptoms in normotensive women with microvascular angina: A randomized placebo-controlled trial.
    Michelsen MM; Rask AB; Suhrs E; Raft KF; Høst N; Prescott E
    PLoS One; 2018; 13(6):e0196962. PubMed ID: 29883497
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of rosuvastatin on risk markers for venous thromboembolism in cancer.
    Ades S; Douce D; Holmes CE; Cory S; Prior S; Butenas S; Callas P; Cushman M
    J Thromb Haemost; 2018 Jun; 16(6):1099-1106. PubMed ID: 29575637
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of a generic rosuvastatin in a real-world setting: prospective, observational clinical study in Lebanese patients.
    Betto M; Fares J; Saliba N; Ballout H
    Ann Saudi Med; 2017; 37(5):366-374. PubMed ID: 28988251
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of the intensive dose of rosuvastatin 40mg/day in patients with acute coronary syndrome and at high risk of cardiovascular disease-ROSUVEES-2.
    Shah CP; Shah BP; Dani SI; Channa BB; Lakshmanan SS; Krishnamani NC; Mehta A; Moorthy P
    Indian Heart J; 2016; 68(6):766-771. PubMed ID: 27931543
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship between inflammation and benefits of early high-dose rosuvastatin on contrast-induced nephropathy in patients with acute coronary syndrome: the pathophysiological link in the PRATO-ACS study (Protective Effect of Rosuvastatin and Antiplatelet Therapy on Contrast-Induced Nephropathy and Myocardial Damage in Patients With Acute Coronary Syndrome Undergoing Coronary Intervention).
    Toso A; Leoncini M; Maioli M; Tropeano F; Di Vincenzo E; Villani S; Bellandi F
    JACC Cardiovasc Interv; 2014 Dec; 7(12):1421-9. PubMed ID: 25523533
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma VEGF and IL-8 Levels in Patients with Mixed Dyslipidaemia. Effect of Rosuvastatin Monotherapy or its Combination at a Lower Dose with Omega-3 Fatty Acids: A Pilot Study.
    Chantzichristos VG; Agouridis AP; Moutzouri E; Stellos K; Elisaf MS; Tselepis AD
    Curr Vasc Pharmacol; 2016; 14(5):474-480. PubMed ID: 27041244
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of Statin Treatment on Modifying Plaque Composition: A Double-Blind, Randomized Study.
    Park SJ; Kang SJ; Ahn JM; Chang M; Yun SC; Roh JH; Lee PH; Park HW; Yoon SH; Park DW; Lee SW; Kim YH; Lee CW; Mintz GS; Han KH; Park SW
    J Am Coll Cardiol; 2016 Apr; 67(15):1772-1783. PubMed ID: 27081016
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and Safety of Adding Omega-3 Fatty Acids in Statin-treated Patients with Residual Hypertriglyceridemia: ROMANTIC (Rosuvastatin-OMAcor iN residual hyperTrIglyCeridemia), a Randomized, Double-blind, and Placebo-controlled Trial.
    Kim CH; Han KA; Yu J; Lee SH; Jeon HK; Kim SH; Kim SY; Han KH; Won K; Kim DB; Lee KJ; Min K; Byun DW; Lim SW; Ahn CW; Kim S; Hong YJ; Sung J; Hur SH; Hong SJ; Lim HS; Park IB; Kim IJ; Lee H; Kim HS
    Clin Ther; 2018 Jan; 40(1):83-94. PubMed ID: 29223557
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intensive statin therapy stabilizes C-reactive protein, but not chemokine in stable coronary artery disease treated with an everolimus-eluting stent.
    Sukegawa H; Maekawa Y; Yuasa S; Anzai A; Kodaira M; Takei M; Sano F; Ueda I; Kawakami T; Hayashida K; Kohno T; Kohsaka S; Abe T; Fukuda K
    Coron Artery Dis; 2016 Aug; 27(5):405-11. PubMed ID: 27105046
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the Effect of Rosuvastatin 2.5 mg vs 20 mg on Coronary Plaque Determined by Angioscopy and Intravascular Ultrasound in Japanese With Stable Angina Pectoris (from the Aggressive Lipid-Lowering Treatment Approach Using Intensive Rosuvastatin for Vulnerable Coronary Artery Plaque [ALTAIR] Randomized Trial).
    Takayama T; Komatsu S; Ueda Y; Fukushima S; Hiro T; Hirayama A; Saito S;
    Am J Cardiol; 2016 Apr; 117(8):1206-12. PubMed ID: 26879069
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design and Rationale for the Endothelin-1 Receptor Antagonism in the Prevention of Microvascular Injury in Patients with non-ST Elevation Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention (ENDORA-PCI) Trial.
    Liou K; Jepson N; Buckley N; Chen V; Thomas S; Russell EA; Ooi SY
    Cardiovasc Drugs Ther; 2016 Apr; 30(2):169-75. PubMed ID: 26814686
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cholesterol Efflux Capacity, High-Density Lipoprotein Particle Number, and Incident Cardiovascular Events: An Analysis From the JUPITER Trial (Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin).
    Khera AV; Demler OV; Adelman SJ; Collins HL; Glynn RJ; Ridker PM; Rader DJ; Mora S
    Circulation; 2017 Jun; 135(25):2494-2504. PubMed ID: 28450350
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial.
    Crouse JR; Raichlen JS; Riley WA; Evans GW; Palmer MK; O'Leary DH; Grobbee DE; Bots ML;
    JAMA; 2007 Mar; 297(12):1344-53. PubMed ID: 17384434
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ischemia and No Obstructive Coronary Artery Disease: Prevalence and Correlates of Coronary Vasomotion Disorders.
    Ford TJ; Yii E; Sidik N; Good R; Rocchiccioli P; McEntegart M; Watkins S; Eteiba H; Shaukat A; Lindsay M; Robertson K; Hood S; McGeoch R; McDade R; McCartney P; Corcoran D; Collison D; Rush C; Stanley B; McConnachie A; Sattar N; Touyz RM; Oldroyd KG; Berry C
    Circ Cardiovasc Interv; 2019 Dec; 12(12):e008126. PubMed ID: 31833416
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.